Cascadia Drug Development Group
Cascadia Drug Development Group (CDDG) is a full-service immunology and drug development consulting firm founded by industry experts passionate about transforming discoveries into therapeutics. They provide strategic advisory, planning, and oversight of therapeutic development activities, focusing on efficiently bridging the gap between discovery, lead generation, and initial clinical proof of concept. With a flexible, virtual structure and externalized research model, CDDG aims to maximize the value of therapeutic opportunities globally, supporting clients in various therapeutic areas including autoimmune, infectious, and oncology.
Industries
Nr. of Employees
small (1-50)
Cascadia Drug Development Group
Products
Industry report: autoimmune disease landscape
A scientific overview of autoimmune disease therapeutics, emerging approaches and key factors for development success; available as a downloadable report.
Industry report: autoimmune disease landscape
A scientific overview of autoimmune disease therapeutics, emerging approaches and key factors for development success; available as a downloadable report.
Services
Consulting on indication selection, portfolio strategy, investment diligence and development roadmaps for early-stage therapeutics.
Hands-on support for target rationale, lead selection, preclinical pharmacology and biomarker strategy to advance candidates toward clinical readiness.
Protocol design, clinical development planning, operations oversight and site/monitoring coordination for early- to late-stage trials.
Regulatory document generation and review including IND/CTA sections, briefing documents and regulatory meeting preparation.
Design and oversight of bioanalytical assay strategies, method development, immunogenicity testing and assay validation oversight.
Genomic/proteomic analyses, machine learning workflows, image analysis and cloud platform development to support target discovery and biomarker development.
Consulting on indication selection, portfolio strategy, investment diligence and development roadmaps for early-stage therapeutics.
Hands-on support for target rationale, lead selection, preclinical pharmacology and biomarker strategy to advance candidates toward clinical readiness.
Protocol design, clinical development planning, operations oversight and site/monitoring coordination for early- to late-stage trials.
Regulatory document generation and review including IND/CTA sections, briefing documents and regulatory meeting preparation.
Design and oversight of bioanalytical assay strategies, method development, immunogenicity testing and assay validation oversight.
Genomic/proteomic analyses, machine learning workflows, image analysis and cloud platform development to support target discovery and biomarker development.
Expertise Areas
- Clinical trial management
- Translational science and target validation
- Immunology and autoimmune disease development
- Protein engineering and therapeutic protein development
Key Technologies
- Bioinformatics and machine learning for molecular data
- Cloud-based genomic data platforms
- Image analysis and spatial biology analytics
- Protein expression and purification
News & Updates
CDDG has released a free report providing an overview of autoimmunity, emerging therapeutic approaches, major players, and success factors, to help make sense of this rapidly evolving space.
Jan L Hillson MD joins as a Partner, bringing extensive experience in drug development for autoimmune diseases, including contributions to Taveneos, Tzield, and nipocalimab.
Wayne Tsuji, a rheumatologist and one of the original Founding Partners, is retiring from active consulting to focus on family and personal pursuits.
A strategic partnership to combine drug development expertise with bioinformatics, data science, machine learning, and AI capabilities.
CDDG is a founding member of a new initiative to make Washington State a hub for life and health science contract research, development, and manufacturing services.
A fast-track regulatory application was submitted for a novel immunomodulatory drug for SARS-CoV-2, developed by Prosit Sole Biotechnology and Orphanon USA.
CDDG has released a free report providing an overview of autoimmunity, emerging therapeutic approaches, major players, and success factors, to help make sense of this rapidly evolving space.
Jan L Hillson MD joins as a Partner, bringing extensive experience in drug development for autoimmune diseases, including contributions to Taveneos, Tzield, and nipocalimab.
Wayne Tsuji, a rheumatologist and one of the original Founding Partners, is retiring from active consulting to focus on family and personal pursuits.
A strategic partnership to combine drug development expertise with bioinformatics, data science, machine learning, and AI capabilities.
CDDG is a founding member of a new initiative to make Washington State a hub for life and health science contract research, development, and manufacturing services.
A fast-track regulatory application was submitted for a novel immunomodulatory drug for SARS-CoV-2, developed by Prosit Sole Biotechnology and Orphanon USA.